SafeHome Pest Solutions — Appendices
The following sensitivity analysis illustrates the impact of key variable changes on the company’s Year 5 EBITDA:
Section 23 · Business Plan
Appendices
The following sensitivity analysis illustrates the impact of key variable changes on the company’s Year 5 EBITDA:
Appendix A: Sensitivity Analysis
The following sensitivity analysis illustrates the impact of key variable changes on the company’s Year 5 EBITDA:
| Scenario | Revenue Impact | EBITDA Impact | Year 5 EBITDA |
|---|---|---|---|
| Base Case | – | – | R2,932,740 |
| Revenue -10% | (R2,450,000) | (R1,960,000) | R972,740 |
| Revenue +10% | +R2,450,000 | +R1,960,000 | R4,892,740 |
| Personnel Costs +10% | – | (R1,512,000) | R1,420,740 |
| Chemical Costs +20% | – | (R637,000) | R2,295,740 |
| Combined Downside (-10% Rev, +10% Costs) | (R2,450,000) | (R3,472,000) | (R539,260) |
Appendix B: Break-even Analysis
The company’s break-even point is reached when total revenue equals total operating costs (including depreciation and interest). Based on the projected cost structure, the monthly break-even revenue is approximately R620,000, which corresponds to approximately 55 active residential subscription clients, 12 active commercial contracts, and 25 once-off residential treatments per month. This break-even point is projected to be reached in Month 18 of operations.
Appendix C: Monthly Cash Flow Projection – Year 1
The monthly cash flow for Year 1 illustrates the cash burn rate during the ramp-up period and the timing of shareholder loan injections:
| Month | Revenue | Operating Costs | Net Cash Flow | Closing Cash |
|---|---|---|---|---|
| Month 1 | R150,000 | (R520,000) | (R370,000) | R3,130,000 |
| Month 2 | R220,000 | (R535,000) | (R315,000) | R2,815,000 |
| Month 3 | R310,000 | (R548,000) | (R238,000) | R2,577,000 |
| Month 4 | R380,000 | (R555,000) | (R175,000) | R2,402,000 |
| Month 5 | R430,000 | (R568,000) | (R138,000) | R2,264,000 |
| Month 6 | R480,000 | (R575,000) | (R95,000) | R2,169,000 |
| Month 7 | R520,000 | (R582,000) | (R62,000) | R2,107,000 |
| Month 8 | R560,000 | (R590,000) | (R30,000) | R2,077,000 |
| Month 9 | R590,000 | (R598,000) | (R8,000) | R2,069,000 |
| Month 10 | R620,000 | (R605,000) | R15,000 | R2,084,000 |
| Month 11 | R640,000 | (R612,000) | R28,000 | R2,112,000 |
| Month 12 | R680,000 | (R620,000) | R60,000 | R2,172,000 |
| Total Year 1 | R5,580,000 | (R6,908,000) | (R1,328,000) | R2,172,000 |
Note: The monthly cash flow above reflects operating cash flows only and excludes the initial capital investment, financing activities, and shareholder loan injections. Total Year 1 revenue in the monthly breakdown differs slightly from the annual projection due to timing of contract commencements and once-off treatment variability.
Appendix D: Detailed Assumptions Register
| Assumption Category | Assumption | Value / Basis |
|---|---|---|
| Pricing | Annual price escalation | 6% (aligned with CPI forecast) |
| Revenue | Residential subscription monthly ARPU | R750 (weighted average) |
| Revenue | Commercial contract monthly ARPU | R5,500 (weighted average) |
| Revenue | Once-off residential treatment average | R1,800 |
| Revenue | Client churn rate (annual) | 15% residential; 10% commercial |
| Cost of Sales | Chemicals as % of revenue | 12-15% (declining with scale) |
| Cost of Sales | Vehicle running costs per unit per month | R8,000 |
| Personnel | Annual salary increase | 7% (aligned with CPI + 1%) |
| Personnel | Performance bonus provision | 10% of base salary |
| Overhead | Office rental escalation | 7% per annum |
| Overhead | Insurance premium escalation | 7% per annum |
| Tax | Corporate income tax rate | 27% |
| Tax | VAT rate | 15% |
| Finance | Bank loan interest rate | Prime + 2% (approx. 13.75%) |
| Finance | Bank loan repayment term | 60 months (equal monthly instalments) |
| Working Capital | Trade receivable days | 45 days |
| Working Capital | Trade payable days | 30 days |
| Capex | Vehicle depreciation | 5 years straight-line |
| Capex | Equipment depreciation | 3 years straight-line |
| Capex | IT and software amortisation | 3 years straight-line |
This document contains proprietary and confidential information. Distribution without written consent is prohibited.